A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
NCT ID: NCT00422461
Last Updated: 2021-10-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
135 participants
INTERVENTIONAL
2007-02-27
2008-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
NCT00779181
A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.
NCT00272961
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
NCT05001945
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
NCT00403481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
placebo
placebo, oral, tablets, once daily, for 28 days
PF-00489791 20 mg titrated to 40 mg
PF-00489791
PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
PF-00489791 4 mg
PF-00489791
PF-00489791 4 mg, oral, tablets, once daily, for 28 days
PF-00489791 10 mg
PF-00489791
PF-00489791 10 mg, oral, tablets, once daily, for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
placebo
placebo, oral, tablets, once daily, for 28 days
PF-00489791
PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
PF-00489791
PF-00489791 4 mg, oral, tablets, once daily, for 28 days
PF-00489791
PF-00489791 10 mg, oral, tablets, once daily, for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. History of mild to moderate hypertension
Exclusion Criteria
2. Secondary, severe, or malignant hypertension
3. History of a significant cardiovascular event within the last 12 months of enrollment
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Research Institute
Los Angeles, California, United States
Apex Research Institute
Santa Ana, California, United States
Orange County Research Center
Tustin, California, United States
University of Connecticut Health Center
Farmington, Connecticut, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Andres Patron, DO, PA
Pembroke Pines, Florida, United States
Commonwealth Biomedical Research, LLC
Madisonville, Kentucky, United States
Twin Cities Clinical Research
Brooklyn Center, Minnesota, United States
Riser Medical Associates
Picayune, Mississippi, United States
Midwest Internists Clinical Research, P.C.
St Louis, Missouri, United States
Triangle Medical Research Associates, LLC
Cary, North Carolina, United States
Medical Research Associates of Charlotte, Inc
Charlotte, North Carolina, United States
Triangle Medical Research Associates
Raleigh, North Carolina, United States
Triangle Medical Research
Raleigh, North Carolina, United States
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States
Sterling Research Group limited
Cincinnati, Ohio, United States
New Orleans Center for Clinical Research
Knoxville, Tennessee, United States
Volunteer Research Group
Knoxville, Tennessee, United States
Clinical Research Associates Incorporated
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A7331007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.